Ha Kung Wong

Ha Kung Wong


Partner, New York

Ha Kung Wong practices general intellectual property law with an emphasis on complex patent and trade secret litigation in pharmaceuticals, biologics and chemistry. Cases Ha Kung has litigated include those related to proton pump inhibitors, anti-epileptic drugs, anti-tussives and other pharmaceuticals. Mr. Wong also has extensive experience with inter partes review (IPR), intellectual property counseling, pre-suit investigations, licensing and due diligence.

Mr. Wong currently is the Chair of the Recruiting Committee, serves as faculty for NITA (the National Institute of Trial Advocacy) and Lawline, and has been named a "Furthered 40" by Lawline for his contributions.

Case Highlight
In re Omeprazole Patent Litigation 
S.D.N.Y. (2002) 

Successfully defended AstraZeneca against claims that two patents relating to the prescription drug Prilosec® are invalid. Prilosec® is a drug used to treat gastric acid secretion disorders.
What Others Say
  • [is someone who has] “an eye for detail” and “goes the extra mile” (Legal 500 2008)
Representative Matters
  • Allergan against Wilshire and Somerset on patents relating to ophthalmic formulations of alcaftadine for once daily treatment of allergic conjunctivitis.
  • AstraZeneca against Andrx, Genpharm, Dr. Reddy and Schwartz Pharma on patents relating to omeprazole and its formulations.
  • Bristol-Myers Squibb against The Regents of the University of Michigan and Repligen Corp. and ZymoGenetics on patents relating to synthetic fusion proteins for regulating the immune system.
  • UCB against Mylan, Dr. Reddy, Sandoz and Cobalt on patents relating to levetiracetam, a leading epilepsy medicine.
  • GlaxoSmithKline against Barr Pharmaceuticals on patents relating to dutasteride, a leading BPH drug.
  • UCB and Celltech against KV Pharmaceutical on patents relating to methylphenidate hydrochloride, an ADHD medicine.
Events / Publications
News & Press